GlaxoSmithKline PLC
LSE:GSK
Intrinsic Value
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. [ Read More ]
The intrinsic value of one
GSK
stock under the Base Case scenario is
2 192.31
GBX.
Compared to the current market price of 1 583.5 GBX,
GlaxoSmithKline PLC
is
Undervalued by 28%.
GSK could be a value trap.A value trap occurs when a stock looks inexpensive based on fundamental analysis but fails to reach its intrinsic valuation over time, often due to underlying issues not reflected in quantitative data.
Scrutinize beyond numbers; assess long-term potential.
GlaxoSmithKline PLC's market capitalization is 64.2B GBX.
GSK stock price is 1 583.5 GBX.
GSK stock price (1583.5 GBX) is 28% less than its Intrinsic Value (2 192.31 GBX).
GSK stock price (1583.5 GBX) is 37% less than its Relative Value (2 510.66 GBX). Open Relative Valuation
GSK has upside potential of 19% compared to the average analyst price target.
Open Wall St Estimates
GSK's Revenue has grown by 3% over the past 12 months.
GSK's D/E (Debt to Equity) is equal to 1.14.
GSK's ROE (Return on Equity) has increased in the last 3 years from 38% to 41%.
GSK's Revenue is forecast to grow at a rate of 6% per year over the next 3 years.
GSK earns more than enough operating income (8B GBP) to safely cover interest payments on its debt (766m GBP).
GSK has positive three-year average ROIC (Return on Invested Capital): 13%. The company is efficient at using invested capital to generate operating income.
GSK's Revenue has been growing by 8% per year for the last 3 years.
GSK's long-term assets (59B GBP) exceed its long-term liabilties (46B GBP).
GSK's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 20%.
GSK's short-term liabilties (21B GBP) exceed its short-term assets (19B GBP).
GSK's ROIC (Return on Invested Capital) has increased in the last 3 years from 11% to 20%.
GSK has positive Operating Income for the last twelve months.
GSK has positive Net Income for the last twelve months.
GSK has positive Net Debt. This means that the company has more debt (15B GBP) than cash and short-term investments (5B GBP).
GSK's ROE (Return on Equity) for the past 12 months is very high and is equal to 41%.
GSK's Altman Z-Score is very low and is equal to 1.8.
GSK has positive Free Cash Flow for the last twelve months.
GSK has positive Gross Profit for the last twelve months.
GSK has very high three-year average ROE (Return on Equity): 59%. The company is very efficient at transforming stockholders' equity into net income.
Valuation Backtest
GlaxoSmithKline PLC
Run backtest to discover the historical profit from buying and selling
GSK
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
GlaxoSmithKline PLC
Balance Sheet Decomposition
GlaxoSmithKline PLC
| Current Assets | 18.6B |
| Cash & Short-Term Investments | 5.2B |
| Receivables | 7.8B |
| Other Current Assets | 5.7B |
| Non-Current Assets | 40.4B |
| Long-Term Investments | 1.2B |
| PP&E | 10B |
| Intangibles | 21.6B |
| Other Non-Current Assets | 7.6B |
| Current Liabilities | 21.1B |
| Accounts Payable | 15.8B |
| Other Current Liabilities | 5.2B |
| Non-Current Liabilities | 24.6B |
| Long-Term Debt | 15.2B |
| Other Non-Current Liabilities | 9.4B |
Earnings Waterfall
GlaxoSmithKline PLC
|
Revenue
|
30.3B
GBP
|
|
Cost of Revenue
|
-8.4B
GBP
|
|
Gross Profit
|
22B
GBP
|
|
Operating Expenses
|
-13.7B
GBP
|
|
Operating Income
|
8.3B
GBP
|
|
Other Expenses
|
-3.4B
GBP
|
|
Net Income
|
4.9B
GBP
|
Free Cash Flow Analysis
GlaxoSmithKline PLC
What is Free Cash Flow?
GSK Profitability Score
Profitability Due Diligence
GlaxoSmithKline PLC's profitability score is 73/100. The higher the profitability score, the more profitable the company is.
Score
GlaxoSmithKline PLC's profitability score is 73/100. The higher the profitability score, the more profitable the company is.
GSK Solvency Score
Solvency Due Diligence
GlaxoSmithKline PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
GlaxoSmithKline PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GSK Price Targets Summary
GlaxoSmithKline PLC
According to Wall Street analysts, the average 1-year price target for
GSK
is 1 882.1 GBX
with a low forecast of 1 212 GBX and a high forecast of 2 656.5 GBX.
Shareholder Return
GSK Price
GlaxoSmithKline PLC
| Average Annual Return | 4.71% |
| Standard Deviation of Annual Returns | 20.38% |
| Max Drawdown | -31% |
| Market Capitalization | 64.2B GBX |
| Shares Outstanding | 4 117 647 100 |
| Percentage of Shares Shorted |
N/A
|
GSK News
Last Important Events
GlaxoSmithKline PLC
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
GlaxoSmithKline PLC
Company Profile
GlaxoSmithKline PLC
Country
Industry
Market Cap
Dividend Yield
Description
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 90,096 full-time employees. The firm researches and develops a range of products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. Its product formulations include tablets, creams/ointments, inhalers, injections, liquids and sterile products. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency virus (HIV), immuno-inflammation and oncology. Its Vaccines business has a portfolio of vaccines to help protect people from a range of diseases throughout their lives. Its vaccines tackle diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Its Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands that consumers trust, and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.
Contact
IPO
Employees
Officers
The intrinsic value of one
GSK
stock under the Base Case scenario is
2 192.31
GBX.
Compared to the current market price of 1 583.5 GBX,
GlaxoSmithKline PLC
is
Undervalued by 28%.
You don't have any saved screeners yet
